The p38α mitogen-activated protein kinase as a central nervous system drug discovery target
Year: 2008
Type: review
Abstract: Protein kinases are critical modulators of a variety of cellular signal transduction pathways, and abnormal phosphorylation events can be a cause or contributor to disease progression in a variety of disorders. This has led to the emergence of protein kinases as an important new class of drug targets for small molecule therapeutics. A serine/threonine protein kinase, p38alpha mitogen-activated protein kinase (MAPK), is an established therapeutic target for peripheral inflammatory disorders because of its critical role in regulation of proinflammatory cytokine production. There is increasing evidence that p38alpha MAPK is also an important regulator of proinflammatory cytokine levels in the central nervous system, raising the possibility that the kinase may be a drug discovery target for central nervous system disorders where cytokine overproduction contributes to disease progression. Development of bioavailable, central nervous system-penetrant p38alpha MAPK inhibitors provides the required foundation for drug discovery campaigns targeting p38alpha MAPK in neurodegenerative disorders.
Source: BMC Neuroscience
Institution: Northwestern University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,990
Awards: Development of Novel p38 MAPK Inhibitors as Therapeutics for CNS Disorders, p38 MAPK in AD-related proinflammatory cytokine up-regulation, G3549828030, G3672347693, Molecular Mechanisms and Modulation of Glial Activation, Drug Discovery Training in Age-Related Disorders, SUPRAMOLECULAR A/BETA--GLIAL INTERACTIONS &CELL RESPONS, G944892781
OpenAlex ID: W2075237564
